Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Madrigal Pharmaceuticals (MDGL) Non-Current Debt (2022 - 2025)

Historic Non-Current Debt for Madrigal Pharmaceuticals (MDGL) over the last 10 years, with Q3 2025 value amounting to $339.8 million.

  • Madrigal Pharmaceuticals' Non-Current Debt rose 19017.14% to $339.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $339.8 million, marking a year-over-year increase of 19017.14%. This contributed to the annual value of $117.6 million for FY2024, which is 180.9% up from last year.
  • Latest data reveals that Madrigal Pharmaceuticals reported Non-Current Debt of $339.8 million as of Q3 2025, which was up 19017.14% from $118.4 million recorded in Q2 2025.
  • Madrigal Pharmaceuticals' 5-year Non-Current Debt high stood at $339.8 million for Q3 2025, and its period low was $48.7 million during Q2 2022.
  • For the 4-year period, Madrigal Pharmaceuticals' Non-Current Debt averaged around $114.6 million, with its median value being $115.8 million (2023).
  • Examining YoY changes over the last 5 years, Madrigal Pharmaceuticals' Non-Current Debt showed a top increase of 19017.14% in 2025 and a maximum decrease of 151.71% in 2025.
  • Quarter analysis of 4 years shows Madrigal Pharmaceuticals' Non-Current Debt stood at $49.3 million in 2022, then surged by 134.29% to $115.5 million in 2023, then grew by 1.81% to $117.6 million in 2024, then soared by 188.98% to $339.8 million in 2025.
  • Its last three reported values are $339.8 million in Q3 2025, $118.4 million for Q2 2025, and $118.0 million during Q1 2025.